/ Home
/ SUBMISSION

/ The BJNANO
/ Diamond Open Access
/ Journal Statistics
/ Editorial Board
/ Community
/ Call for papers

/ Latest Articles
/ Most accessed
/ Thematic issues
/ Volumes
/ Authors

/ Alerts

/ TWITTER
/ LINKEDIN
/ Mastodon
/ RSS FEED

Empty search

Article Type

Publication Date Range

Search Tips

This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.

Search Examples

aromatic	the word “aromatic”
aromatic aldehyde	the word “aromatic” OR “aldehyde”
+aromatic +aldehyde	both words “aromatic” AND “aldehyde”
+aromatic -aldehyde	the word “aromatic” but NOT “aldehyde”
“aromatic aldehyde”	the exact phrase “aromatic aldehyde”
benz*	words which begin with “benz”, such as “benzene” or “benzyl”
benz*yl	words that begin with “benz” and end with “yl”, such as “benzyl” or “benzoyl”
benzyl~	words that are close to the word “benzyl”, such as “benzoyl” (i.e., fuzzy search)

BROWSE
Latest Articles
Most accessed
thematic issues
volumes
authors

BROWSE

Latest Articles Most Accessed Thematic Issues Volumes Authors

Author

1 article(s) from Baykal, Abdulhadi

cisplatin nanocomposite formulation

B. Rabindran Jermy,
Vijaya Ravinayagam,
Widyan A. Alamoudi,
Dana Almohazey,
Hatim Dafalla,
Lina Hussain Allehaibi,
Abdulhadi Baykal,
Muhammet S. Toprak and
Thirunavukkarasu Somanathan

Beilstein J. Nanotechnol. 2019, 10, 2217–2228, doi:10.3762/bjnano.10.214

PDF

Scheme 1: Schematic representation of CuFe₂O₄/HYPS/cisplatin nanoformulation.

Jump to Scheme 1

Figure 1: Powder XRD patterns of CuFe₂O₄/HYPS with different Cu concentrations (x = 0.08, 0.10, 0.12, 0.15 an...

Jump to Figure 1

Figure 2: BET adsorption–desorption isotherm and pore size distribution of (a) HYPS and (b) 30 wt% CuFe₂O₄/HY...

Jump to Figure 2

Figure 3: FTIR spectra of HYPS and 30 wt % CuFe₂O₄/HYPS.

Jump to Figure 3

Figure 4: Transmission electron microscopy of (a, b) 30 wt % CuFe₂O₄/HYPS at different scale magnifications a...

Jump to Figure 4

Figure 5: Vibrating sample magnetometer spectrum of 30 wt % CuFe₂O₄/HYPS.

Jump to Figure 5

Figure 6: DR-UV–visible spectra of (a) CuFe₂O₄/HYPS and (b) cisplatin/CuFe₂O₄/HYPS.

Jump to Figure 6

Figure 7: Percentage cumulative cisplatin release in tumor pH 5 conditions for 72 h in (a) CuFe₂O₄/HYPS, (b) ...

Jump to Figure 7

Figure 8: Percentage cell viability using MTT assay on the MCF-7 cell line. The cells were treated with the f...

Jump to Figure 8

Figure 9: EC₅₀ values for each condition. Data sets from Figure 8 were used to extrapolate the line equation of each ...

Jump to Figure 9

Album

Supp Info

Full Research Paper

Published 12 Nov 2019

Full text

Other Beilstein-Institut Open Science Activities

/ Help / Support & Contact / Alerts / Privacy Policy / Terms & Conditions / Impressum

Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe2O4/silica/cisplatin nanocomposite formulation

Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe₂O₄/silica/cisplatin nanocomposite formulation